NOVAVAX INC
Congressional Trades
| Politician | Stock | Type | Filed | Traded | |
|---|---|---|---|---|---|
Pat RobertsSenate · R · KS |
NVAXNOVAVAX INC · Stock |
Sale $1,001 - $15,000 |
Nov 5, 2020 | Oct 13, 2020 | Filing ↗ |
Pat RobertsSenate · R · KS |
NVAXNOVAVAX INC · Stock |
Purchase $1,001 - $15,000 |
Aug 30, 2020 | Aug 17, 2020 | Filing ↗ |
Whale Activity
- Increased71
- New29
- Held64
- Decreased83
- Closed37
- No prior filing15
| Filer | Shares | Value | Change |
|---|---|---|---|
| BlackRock, Inc. | 15.6M | $168.6M | increased |
| SHAH CAPITAL MANAGEMENT | 12.2M | $131.6M | decreased |
| STATE STREET CORP | 8.8M | $95.4M | decreased |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 7.2M | $78.4M | decreased |
| VANGUARD CAPITAL MANAGEMENT LLC | 7.2M | $78.2M | decreased |
| Sanofi | 6.9M | $74.4M | held |
| D. E. Shaw & Co., Inc. | 5.7M | $62.0M | increased |
| TWO SIGMA INVESTMENTS, LP | 5.5M | $59.6M | increased |
| GEODE CAPITAL MANAGEMENT, LLC | 4.2M | $45.7M | increased |
| COATUE MANAGEMENT LLC | 3.8M | $41.5M | held |
| BANK OF AMERICA CORP /DE/ | 3.8M | $41.0M | increased |
| GOLDMAN SACHS GROUP INC | 3.0M | $32.2M | decreased |
Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.
Insider Trading
No open-market insider buys or sells in the last two years.
Recent Insider Transactions
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Rodgers Richard JDirector | Option exercise | +18.9K | — | — | Jun 20, 2026 | Form 4 ↗ |
| King Rachel K.Director | Option exercise | +18.9K | — | — | Jun 20, 2026 | Form 4 ↗ |
| DOUGLAS RICHARDDirector | Option exercise | +18.9K | — | — | Jun 20, 2026 | Form 4 ↗ |
| MCGLYNN MARGARET GDirector | Option exercise | +18.9K | — | — | Jun 20, 2026 | Form 4 ↗ |
| MOTT DAVID MDirector | Option exercise | +18.9K | — | — | Jun 20, 2026 | Form 4 ↗ |
| Alton Gregg HDirector | Option exercise | +18.9K | — | — | Jun 20, 2026 | Form 4 ↗ |
| Newton Charles W.Director | Option exercise | +9,520 | $0.00 | $0 | Apr 25, 2026 | Form 4 ↗ |
| Shiver John W.Director | Option exercise | +7,947 | $0.00 | $0 | Mar 10, 2026 | Form 4 ↗ |
| Kelly James PatrickEVP, CFO and Treasurer | Tax withholding | −5,904 | $9.98 | $59K | Mar 7, 2026 | Form 4 ↗ |
| Kelly James PatrickEVP, CFO and Treasurer | Option exercise | +12.2K | $0.00 | $0 | Mar 7, 2026 | Form 4 ↗ |
| Kelly James PatrickEVP, CFO and Treasurer | Tax withholding | −20.9K | $9.49 | $198K | Mar 3, 2026 | Form 4 ↗ |
| Kelly James PatrickEVP, CFO and Treasurer | Option exercise | +43.2K | $0.00 | $0 | Mar 3, 2026 | Form 4 ↗ |
| Jacobs John CPresident and CEO · Director | Tax withholding | −69.3K | $9.49 | $658K | Mar 3, 2026 | Form 4 ↗ |
| Jacobs John CPresident and CEO · Director | Option exercise | +150.2K | $0.00 | $0 | Mar 3, 2026 | Form 4 ↗ |
| O'Hara ElaineEVP, Chief Strategy Officer | Tax withholding | −22.4K | $9.49 | $213K | Mar 3, 2026 | Form 4 ↗ |
| O'Hara ElaineEVP, Chief Strategy Officer | Option exercise | +56.3K | $0.00 | $0 | Mar 3, 2026 | Form 4 ↗ |
| Casey Mark JEVP, Chief Legal Officer | Tax withholding | −11.4K | $9.49 | $108K | Mar 3, 2026 | Form 4 ↗ |
| Casey Mark JEVP, Chief Legal Officer | Option exercise | +37.5K | $0.00 | $0 | Mar 3, 2026 | Form 4 ↗ |
| Draghia-Akli RuxandraEVP, Research & Development | Tax withholding | −11.3K | $9.49 | $107K | Mar 3, 2026 | Form 4 ↗ |
| Draghia-Akli RuxandraEVP, Research & Development | Option exercise | +26.7K | $0.00 | $0 | Mar 3, 2026 | Form 4 ↗ |
Fund Holders
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST | 7.5M | $70.9M | 0.66% | Jun 30, 2026 |
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 5.2M | $49.0M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF iShares Trust | 3.9M | $36.9M | 0.04% | Jun 30, 2026 |
| VANGUARD SMALL-CAP INDEX FUND VANGUARD INDEX FUNDS | 3.8M | $35.5M | 0.02% | Jun 30, 2026 |
| VANGUARD SMALL-CAP GROWTH INDEX FUND VANGUARD INDEX FUNDS | 2.2M | $20.4M | 0.04% | Jun 30, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 1.9M | $17.8M | 0.02% | Jun 30, 2026 |
| iShares Russell 2000 Value ETF iShares Trust | 1.4M | $13.5M | 0.09% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund Fidelity Salem Street Trust | 1.7M | $12.2M | 0.04% | Jul 31, 2026 |
| iShares Biotechnology ETF iShares Trust | 1.1M | $10.5M | 0.12% | Jun 30, 2026 |
| PIMCO RAE US Small Fund PIMCO Equity Series | 1.0M | $9.6M | 0.25% | Jun 30, 2026 |
Mutual funds and ETFs whose N-PORT filings list NVAX's shares (CUSIP 670002401), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
- STATE STREET CORPORATIONSCHEDULE 13G · passive (13G) · 8.8M shares5.4%
Nov 10, 2026 · ↗ - Himanshu H. ShahSCHEDULE 13G · passive (13G) · 10.7M shares6.5%
Oct 16, 2026 · ↗ - Shah Capital Fund LLCSCHEDULE 13G · passive (13G) · 6.2M shares3.8%
Oct 16, 2026 · ↗ - Shah Capital ManagementSCHEDULE 13G · passive (13G) · 10.5M shares6.4%
Oct 16, 2026 · ↗ - Himanshu H. ShahSCHEDULE 13D/A · activist (13D) · 10.7M shares6.5%
Oct 16, 2026 · ↗ - Shah Capital Fund LLCSCHEDULE 13D/A · activist (13D) · 6.2M shares3.8%
Oct 16, 2026 · ↗ - Shah Capital ManagementSCHEDULE 13D/A · activist (13D) · 10.5M shares6.4%
Oct 16, 2026 · ↗ - STATE STREET CORPORATIONSCHEDULE 13G · passive (13G) · 11.7M shares7.1%
Aug 7, 2026 · ↗ - Himanshu H. ShahSCHEDULE 13D/A · activist (13D) · 14.8M shares9.0%
May 15, 2026 · ↗ - Shah Capital Opportunity Fund LPSCHEDULE 13D/A · activist (13D) · 14.0M shares8.5%
May 15, 2026 · ↗
Corporate Lobbying
- BALLARD PARTNERS, LLCNOVAVAX, INC. · 2026 Q3 · MED$50K
Filing ↗ - BROWNSTEIN HYATT FARBER SCHRECK, LLPNOVAVAX, INC. · 2026 Q3 · HCR$50K
Filing ↗ - NOVAVAX, INCNOVAVAX, INC · 2026 Q3 · HCR$120K
Filing ↗ - NOVAVAX, INCNOVAVAX, INC · 2026 Q2 · HCR$130K
Filing ↗ - BROWNSTEIN HYATT FARBER SCHRECK, LLPNOVAVAX, INC. · 2026 Q2 · HCR$50K
Filing ↗
Government Contracts
No federal contract awards found for NOVAVAX INC.
U.S. Patents
No USPTO patent applications found for NOVAVAX INC.
Annual Financials
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $1.12B | $682.2M | $983.7M | $1.98B | $1.15B |
| Operating income | $452.8M | -$248.9M | -$566.5M | -$644.7M | -$1.69B |
| Net income | $440.3M | -$187.5M | -$545.1M | -$657.9M | -$1.74B |
| Diluted EPS | $2.58 | -$1.23 | -$5.41 | -$8.42 | -$23.44 |
| Operating cash flow | -$244.6M | -$87.3M | -$714.0M | -$415.9M | $322.9M |
| Cash and equivalents | $240.6M | $530.2M | $568.5M | $1.34B | $1.52B |
| Total assets | $1.18B | $1.56B | $1.80B | $2.26B | $2.58B |
| Total liabilities | $1.30B | $2.18B | $2.51B | $2.89B | $2.93B |
| Shareholders' equity | -$127.8M | -$623.8M | -$716.9M | -$634.1M | -$351.7M |
As NOVAVAX INC tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Feb 26, 2026 ↗
Stock Splits
- 1-for-20Reverse splitMay 10, 2019
Split dates and ratios from the price history · Close Prices from Tiingo.com
Material Events (8-K)
- 8-K · Items 2.02, 9.01Results of operationsNov 5, 2026
EDGAR ↗ - 8-K · Items 7.01, 8.01, 9.01Reg FD disclosure · Other eventsOct 29, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsAug 6, 2026
EDGAR ↗ - 8-K · Items 5.07Shareholder voteJun 23, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsMay 6, 2026
EDGAR ↗ - 8-K · Items 2.01Acquisition or dispositionDec 30, 2024
EDGAR ↗

